CurrentBlue Cross Blue Shield - IowaPolicy 05.02.36

Immediate‑release opioid combination analgesics (IR opioid combos) — coverage, quantity limits, and clinical limitations

This drug policy governs coverage, quantity limits, and clinical limitations for immediate‑release opioid combination products (opioid + acetaminophen/NSAID/caffeine/etc.) for Wellmark Blue Cross and Blue Shield members; it affects prescribers, pharmacists, and prior authorization reviewers. Applies to benefits/contracts as described by the payer.

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyImmediate‑release opioid combination analgesics (IR opioid combos)

Policy CodePolicy 05.02.36

Change TypeNo material changes

Effective DateJan 5, 2025

Next Review DateApr 1, 2026

Key ActionVerify member benefits and ensure dispensed quantity does not exceed product labeling and payer limits (≤90 MME/day; acetaminophen ≤4 g/day; ibuprofen ≤3200 mg/day) to avoid claim rejection.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

90 MME/dayMME limit

4 g/dayAcetaminophen max

3200 mg/dayIbuprofen max

30- or 90-daySupplies without PA

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Apadaz labeled duration

Coverage Criteria

Covered indications and clinical limitations

Covered when ALL of the following are met:

Indication: Product is being used for an FDA‑approved or compendial indication (management of acute pain severe enough to require an opioid analgesic).

Per product labeling and policy description.

Prior non‑opioid therapy: Alternative treatment options (e.g., non‑opioid analgesics) have not been tolerated or are not expected to be tolerated, or have not provided adequate analgesia or are not expected to provide adequate analgesia.

Applies across listed products per Limitations of Use statements.

Duration limits: Use is limited to product‑specific labeled durations for products with short‑term indications (example: Apadaz no more than 14 days; Ultracet five days or less).

See individual product labeling.

Quantity limits: Dispensed supply must not exceed the product labeling maximum daily dose and must comply with payer quantity limits (monthly/3‑month limits that correspond to ≤ 90 MME/day unless FDA‑labeled strength exceeds 90 MME/day, acetaminophen or aspirin ≤ 4 g/day, ibuprofen ≤ 3200 mg/day).≤ 90 MME/day; ≤ 4 g APAP/ASA; ≤ 3200 mg IBU

Claims will reject when requesting more than initial quantity limits.

Quantity limit criteria

Covered when dispensing does not exceed the product/strength specific quantity limits and respects non‑opioid component and MME maxima.

General limits: Dispensed quantity must not exceed the product/strength specific per‑25‑day (approx monthly) and per‑75‑day (3‑month) limits listed in the policy table and must correspond to ≤ 90 MME/day and non‑opioid component maxima (acetaminophen or aspirin ≤ 4 g/day; ibuprofen ≤ 3200 mg/day).see table entries

Quantities above initial limits will reject at claims adjudication.

Accumulation groups: Quantity limits accumulate drugs into specified groups (acetaminophen solutions; acetaminophen tablets/capsules; aspirin tablets/capsules; ibuprofen tablets; celecoxib tablets) up to the highest quantity in each group depending on claim processing order.

See policy table 'Accumulation Group' for details.

Verify individual member benefits and contract applicability before assuming coverage. Wellmark determines medical necessity only if the benefit exists and no contract exclusions apply. This policy may not apply to Federal Employee Program (FEP) members; benefits for FEP are determined by the Federal Employee Program.

The CDC guideline exclusions for patients with sickle cell disease, cancer, or those receiving palliative/end‑of‑life care do not change the quantity limits in this policy. Because immediate‑release opioid combination products contain non‑opioid components with FDA‑labeled daily maxima (acetaminophen, aspirin, ibuprofen), the policy’s acetaminophen/aspirin and ibuprofen limits apply to all patients regardless of concomitant conditions.

Claims will reject when the dispensed quantity exceeds the payer’s initial quantity limits. Coverage is allowed without prior authorization only when the monthly quantity does not exceed product labeling maximum daily dose and the policy thresholds: ≤ 90 MME/day (unless FDA‑labeled strength exceeds 90 MME/day), ≤ 4 g/day acetaminophen or aspirin, and ≤ 3200 mg/day ibuprofen. Requests above these quantity/MME/APAP/IBU thresholds will be denied at adjudication with a message that quantity limits are exceeded.

Coding and Dosing Limits

inv-07: Maximum daily MME — ≤ 90 MME/day (unless FDA-labeled strength/dose/frequency exceeds 90 MME/day)

Maximum daily MME≤ 90 MME/day (unless FDA‑labeled strength/dose/frequency exceeds 90 MME/day)

ApplicationMonthly quantity limits correspond to the ≤ 90 MME/day threshold and are enforced at claims adjudication

Exception noteIf FDA‑labeled maximum daily dose for a product exceeds 90 MME/day, the labeled maximum may apply instead of the 90 MME/day cap

inv-08: Maximum daily acetaminophen or aspirin — ≤ 4 g/day

Acetaminophen maximum≤ 4 g/day (4000 mg/day)

Policy applicationNon-opioid component limits (including acetaminophen) are enforced for all patients regardless of concomitant conditions

Provider Actions and Operational Notes

Denial Risk

Quantity limit exceedance

Coverage is provided without prior authorization for a 30‑day or 90‑day supply of immediate‑release opioid combination products when the monthly quantity does not exceed product labeling and the policy limits (including ≤ 90 MME/day unless the FDA‑labeled dosing exceeds 90 MME/day, ≤ 4 g/day acetaminophen or aspirin, and ≤ 3200 mg/day ibuprofen). If the patient is requesting more than the initial quantity limit, the claim will reject with a message indicating that quantity limits are exceeded.

Initial monthly and 3‑month limits are enforced at claim adjudication; claims exceeding the listed monthly limits will reject.
Quantity limits accumulate across defined product groups (see policy quantity chart). Exceeding accumulated limits will cause claim rejection.
Quantities above initial limits are not approved due to risks from exceeding FDA‑labeled dosing of non‑opioid components (acetaminophen, aspirin, ibuprofen).

Documentation Required

Benefit verification

Background

Immediate‑release opioid combination products are intended for the management of acute pain severe enough to require an opioid analgesic when alternative, non‑opioid treatments are inadequate. Because of risks of addiction, abuse, and the presence of non‑opioid components with FDA‑labeled maxima, these combination products are generally reserved for patients who have not tolerated or not achieved adequate analgesia with non‑opioid options. Some products have labeled short‑term indications (for example, Apadaz is indicated for no more than 14 days), and labeled duration should guide prescribing and quantity limits.

Definitions and Labeling Notes

inv-21: Short-term opioid use (Apadaz) — Apadaz indicated short-term ≤14 days

Apadaz indicationShort‑term use only — no more than 14 days for acute pain

Use restrictionReserve for patients who have not tolerated or not achieved adequate analgesia with non‑opioid alternatives

ReasonRisks of addiction, abuse, and misuse even at recommended doses

inv-22: APAP/aspirin/ibuprofen maxima — acetaminophen 4,000 mg/day; aspirin 4,000 mg/day; ibuprofen 3,200 mg/day

Acetaminophen maximum4,000 mg/day

Aspirin maximum4,000 mg/day

Initial Therapy Quantity Limits

Coverage without prior authorization for initial supplies when ALL of the following are met:

Supply duration: Initial coverage provided without prior authorization for a 30‑day (per 25 days) or 90‑day (per 75 days) supply, provided the monthly quantity does not exceed product labeling maximum daily dose and payer thresholds.30‑ or 90‑day per table

Per prior authorization policy statement.

MME and non‑opioid limits: Initial monthly and 3‑month quantities must correspond to ≤ 90 MME/day unless the FDA‑labeled strength/dose/frequency exceeds 90 MME/day, and must maintain non‑opioid component limits (acetaminophen/aspirin ≤ 4 g/day; ibuprofen ≤ 3200 mg/day).≤ 90 MME/day; ≤ 4 g APAP/ASA; ≤ 3200 mg IBU

Claims exceeding listed monthly quantity limits will reject.

Step Therapy / Limitation of Use

Step	Requirement	Rationale / Notes
1	Opioid combination products reserved for patients who have not tolerated or not achieved adequate analgesia with alternative non‑opioid treatments (e.g., acetaminophen, NSAIDs).	Per product labeling Limitations of Use: reserve opioids for patients when alternative treatments are inadequate or not tolerated; applies across listed products (Apadaz, codeine/APAP, hydrocodone/APAP, hydrocodone/ibuprofen, Seglentis, Ultracet).

Step	Requirement	Rationale / Notes
1	When initiating opioids, prescribe the lowest effective dosage and use caution when increasing dose; no explicit multi‑step sequence is required by policy.	Aligns with CDC guidance to start at the lowest effective dose for opioid‑naïve patients; policy does not define additional sequential step edits beyond reserving opioids after non‑opioid failure.

Product-Specific Quantity Limits

inv-27: APAP/codeine solution 120-12 mg/5 mL — 2700 mL/month (90 mL/day equivalent)

Monthly solution limitAPAP/codeine solution 120/12 mg per 5 mL = 2700 mL/month (90 mL/day equivalent)

Corresponding MMEEquivalent ~32.4 MME/day for the listed labeled dosing example

3‑month limit8100 mL/3 months (90 mL/day equivalent)

inv-28: APAP/codeine tab 300/15 mg — 400 tabs/month (13.34 tabs/day)

Tablet monthly limitAPAP/codeine 300/15 mg = 400 tabs/month (13.34 tabs/day)

MME exampleApproximate 30 MME/day for the 400 tabs/month limit (per product table)

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyImmediate‑release opioid combination analgesics (IR opioid combos)

Policy CodePolicy 05.02.36

Change TypeNo material changes

Effective DateJan 5, 2025

Next Review DateApr 1, 2026

SourceLink

On This Page

Claims enforcementMonthly/3‑month quantity limits are set to ensure acetaminophen does not exceed 4 g/day

inv-09: Maximum daily ibuprofen — ≤ 3200 mg/day

Ibuprofen maximum≤ 3200 mg/day

RationaleFDA‑labeled maximum daily dose for ibuprofen is 3200 mg and is enforced by the policy

Quantity limitsPer‑product monthly limits are calculated to ensure ibuprofen does not exceed 3200 mg/day

inv-10: Maximum non-opioid component daily doses — acetaminophen ≤ 4 g/day; aspirin ≤ 4 g/day; ibuprofen ≤ 3200 mg/day

Acetaminophen≤ 4 g/day (4000 mg/day)

Aspirin≤ 4 g/day (4000 mg/day)

Ibuprofen≤ 3200 mg/day

inv-11: MME threshold referenced — ≤ 90 MME/day (monthly limits correspond)

Referenced MME threshold≤ 90 MME/day (monthly quantity limits correspond to this threshold)

EnforcementClaims exceeding monthly limits that correspond to > 90 MME/day will reject at adjudication

Standards linkageQuantity tables are constructed so per‑25‑day and per‑75‑day limits align with the ≤ 90 MME/day cap

Verify individual member benefits and contract exclusions prior to prescribing or dispensing. Benefit determinations depend on the member's contract in effect at the time services are rendered; exclusions, limitations, or exceptions may apply.

Confirm coverage for the specific member and plan, including any pharmacy benefit limits or prior authorization requirements not covered by this policy.
Wellmark (Blue Cross Blue Shield - Iowa) determines medical necessity only if the benefit exists and no contract exclusions apply.

Billing Rule

Billing codes

Use appropriate billing and diagnostic codes when reporting services. Incorrect coding can affect adjudication and application of quantity limits.

Report services with applicable CPT, HCPCS (alpha‑numeric), Revenue, and ICD‑10 diagnosis codes.
Ensure NDC and drug strength are accurate on pharmacy claims so quantity and MME calculations apply correctly.

Step Therapy

Use after non-opioid failure

Reserve immediate‑release opioid combination products for patients who have not tolerated or not achieved adequate analgesia with non‑opioid alternatives, or for whom such alternatives are not expected to be tolerated or provide adequate analgesia.

Applies to agents such as benzhydrocodone/acetaminophen (Apadaz), codeine/acetaminophen, and hydrocodone/acetaminophen.
Apadaz is indicated for short‑term use (no more than 14 days); consider non‑opioid options first and limit supply accordingly.

Note

Guidance references (CDC recommendations)

Follow CDC guidance when initiating and continuing opioid therapy: prescribe the lowest effective dosage for opioid‑naïve patients and exercise caution when increasing dosage; carefully evaluate benefits and risks before dose increases.

CDC recommends clinicians avoid increasing dosages above levels likely to yield diminishing returns (many patients do not benefit from dosages ≥ 50 MME/day and risks increase with higher dosages).
Policy quantity limits align with CDC recommendations by limiting monthly quantities to amounts corresponding to ≤ 90 MME/day and to FDA‑labeled maximums for non‑opioid components.

Product/strength specific limits: Specific numeric initial 1‑month and 3‑month limits are applied per product and strength as listed in the policy table (examples include APAP/codeine solution 2700 mL/month; APAP/codeine 300/15 mg = 400 tabs/month; benzhydrocodone/APAP 4.08/325 mg = 168 tabs/month).varies by product (see table)

Detailed per‑drug numeric limits located in the policy table.

Initial therapy limits by product

Initial quantity limits set to correspond to labeled short‑term supplies and MME/non‑opioid maxima.

Apadaz (benzhydrocodone/acetaminophen): Initial 1‑month and 3‑month limits allow a 14‑day supply (168 tablets) consistent with labeled dosing (1–2 tablets q4–6h; maximum 12 tablets/day); because the product is indicated for short‑term use, the 3‑month limit does not apply beyond the labeled short course.168 tabs per 25 days

Product indicated for short‑term use (≤14 days).

Hydrocodone/ibuprofen products: Initial limits reflect labeled short‑term dosing (examples: hydrocodone/ibuprofen 5/200 mg formulations limited to 50 tabs per 25 days consistent with max 5 tabs/day for 10 days).50 tabs per 25 days for typical short‑term strengths

Short‑term labeled use; 3‑month limit may not apply for very short‑term products.

Ultracet (tramadol/acetaminophen): Initial limits correspond to labeled short‑term use (five days or less) with an example limit of 40 tabs per 25 days for the listed strength (max 8 tabs/day).40 tabs per 25 days

Ultracet labeled for ≤5 days.

Seglentis (celecoxib/tramadol): Initial limit set to labeled maximum dosing of 4 tablets/day (policy sets 120 tabs per 25 days; 360 tabs per 75 days).4 tabs/day; 120 tabs per 25 days

Labeled dosing 2 tabs q12h, max 4 tabs/day.

3‑month limit1200 tabs/3 months (13.34 tabs/day)

inv-29: Benzhydrocodone/APAP 4.08 mg/325 mg — 168 tabs/month (12 tabs/day)

Benzhydrocodone/APAP monthly limit4.08 mg/325 mg = 168 tabs/month (12 tabs/day)

Labeled dosingLabeled MAX 12 tabs/day for 14 days (short‑term use)

3‑month noteInitial 3‑month limit marked as 'Does Not Apply' for listed benzhydrocodone strengths

inv-30: Seglentis (celecoxib/tramadol 56/44 mg) — 120 tabs/month (4 tabs/day)

Seglentis monthly limitCelecoxib/tramadol 56/44 mg (Seglentis) = 120 tabs/month (4 tabs/day)

Labeled dosingLabeled MAX 4 tabs/day (q12h dosing)

3‑month limit360 tabs/3 months (4 tabs/day)

inv-31: Multiple IR opioid combination products — product/strength specific per 25-day and per 75-day maximum quantities listed (examples included)

Product/strength specificityQuantity limits are product‑ and strength‑specific with per‑25‑day (approx monthly) and per‑75‑day (3‑month) maximums listed in the policy table

Examples providedExamples include benzhydrocodone/APAP, hydrocodone/APAP (multiple strengths), oxycodone/APAP (multiple strengths), hydrocodone/ibuprofen, oxycodone/aspirin, and various solution formulations

EnforcementClaims exceeding the per‑product monthly limits will reject at adjudication